RoosterBio Inc. launches new stem cell product format enabling rapid, scalable cell manufacturing and 3D bioprinting

Share Article

Well-characterized and high-volume living cell systems provide engineered solutions for rapid product development and commercial translation

Based upon strong market demand, RoosterBio Inc has announced the commercial launch of RoosterVial-hBM-50M MSC, a single vial containing 50 million human bone-marrow derived mesenchymal stem/stromal cells. This unprecedented, ultra-high cell number product configuration enables Regenerative Medicine organizations to accelerate scale-up and product development activities. RoosterBio’s core technology, which includes cell and media systems, allows tissue engineers, biofabricators, 3D bioprinters and cell therapy developers to instantly scale up, using simplified and standardized methods.

The 50 million hMSC vial delivers immediate cell biomass without the need for prior expansion. This results in saving significant time, resources and expense during bioprocess scale-up optimization. Since the system contains the most well-characterized hMSCs available on the market, the industry is assured robust and reproducible results. As with other RoosterBio products, this 50 million cell product is capable of greater than 100-fold expansion (>5 billion cells) within two weeks when cultured in RoosterBio medium. Prior to this technology, obtaining such cell numbers so rapidly was virtually impossible.

RoosterBio continues to broaden their portfolio of product formats, providing solutions for an extensive range of Regenerative Medicine therapeutic categories. The evolving product portfolio enables researchers and product developers to perform small scale screening studies, large scale development studies, and now, scale-up manufacturing bioprocess experiments using the 50 million cell product. Rapid prototyping of 3D bioprinted tissues utilizing hMSCs as the primary component of the cellular “bioink” is also now achievable. The Company offers various product configurations including 1 million cell vials, 10 million cell vials, and high performance media systems, as well as pre-assembled working cell banks and kits for rapidly achieving stem cell biomass.
Jon Rowley, CEO of RoosterBio stated: "The Industry has published a technology roadmap for scalable cell manufacturing and 3D bioprinting, yet the materials needed to test and implement these technologies are not readily available. RoosterBio is addressing this major roadblock with innovative product formats that enable users to do more work, faster, and with much less out-of-pocket expense."

RoosterBio’s mission is to accelerate the development and commercialization of Regenerative Medicine products, by providing standardized stem cell product platforms that enable rapid translation of discoveries into product development. For more information, please email Priya Baraniak at priya@roosterbio.com or phone 1-412-606-1160.

About RoosterBio

RoosterBio is a privately held biofabrication tools company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, where researchers spend newly found time and money performing more high-value experiments, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio and adult stem cells, you can visit http://www.roosterbio.com, follow on twitter (@RoosterBio), or read the highly-acclaimed blog “Democratizing Cell Technologies” (http://www.roosterbio.blogspot.com).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Priya Baraniak
Follow us on
Visit website